Comparing the current results to its competitors, Procept Biorobotics reported Revenue increase in the 1 quarter 2026 by 19.93 % year on year. The sales growth was above Procept Biorobotics's competitors' average revenue growth of 8.4 %, achieved in the same quarter.
Procept Biorobotics Corporation, slower than the average decrease reported by the company's competitors of -38.92 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -38.92 %
Procept Biorobotics's Comment on Competition and Industry Peers
The company operates in a competitive and rapidly evolving industry for benign prostatic hyperplasia (BPH) treatments. Its Aquablation therapy, delivered through robotic systems, offers a distinct approach; however, current and future products face competition from companies with greater financial, technical, and marketing resources. Competitors often have larger customer bases, broader relationships, longer operating histories, stronger brand recognition, and have addressed reimbursement challenges. Primary competitors include resective surgical treatments such as devices used in the transurethral resection of the prostate (TURP) procedure and laser-based therapies marketed by Boston Scientific Corporation. The company also competes with non-resective and non-surgical treatments, including UroLift marketed by Teleflex Incorporated and Rezum marketed by Boston Scientific Corporation.
Overall company sales advanced by 19.93 % Procept Biorobotics outperformed its competitors in this segment and improved market share, to approx. 0.14 %. << More on PRCT Market Share.
*Market share is calculated based on total revenue.
News about Procept Biorobotics Corporation Contracts
August 21, 2024
In a significant advancement for urological care, PROCEPT BioRobotics recently announced the FDA clearance of its HYDROS Robotic System. This system represents a cutting-edge, artificial intelligence-powered platform specifically designed to enhance the Aquablation Therapy, a minimally invasive treatment for benign prostatic hyperplasia (BPH). With a paradigm shift toward digital health solutions in surgical environments, the HYDROS system aims to foster improvements not only in clinical outcomes but also in the overall experience for surgeons and clinical staff.Aquablation Therapy involves using a high-velocity stream of warm saline to remove excess prostate tissue, alleviating urinary symptoms associated w...
June 17, 2024
SAN JOSE, Calif., June 17, 2024 In a significant stride towards revolutionizing urological care, PROCEPT BioRobotics Corporation (Nasdaq: PRCT), a pioneering surgical robotics company, proudly announced today that the American Medical Association (AMA) has established a new Current Procedural Terminology (CPT) Category I code for its groundbreaking Aquablation therapy. This new code is a testament to Aquablation therapy s impact and clinical efficacy in treating benign prostatic hyperplasia (BPH), a prevalent and often debilitating condition among older men. Unveiling the Next Generation in Urological CarePROCEPT BioRobotics has been at the forefront of developing transformative solutions in urology, with ...
Boston Scientific Corporations business model centers on creating innovative medical devices for diverse specialties, aimed at addressing unmet medical needs and enhancing patient outcomes. The company sells its products to healthcare professionals and hospitals globally, supported by robust sales and distribution networks. It prioritizes research and development to continually introduce new technologies and solutions.
Angiodynamics Inc is a medical technology company that focuses on the development and commercialization of devices and treatments for minimally invasive procedures. Their business model centers around the manufacturing and sale of innovative medical devices such as catheters, lasers, and fluid systems used in the diagnosis and treatment of various vascular conditions. They primarily generate revenue through the sale of these products to healthcare providers and hospitals worldwide.
Sources:
Procept Biorobotics Corporation’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Procept Biorobotics Corporation versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
